Evidence map›Paper›PMID 38550937›Full record

ReviewCambridge prisms. Precision medicine2023

Making inroads to precision medicine for the treatment of autoimmune diseases: Harnessing genomic studies to better diagnose and treat complex disorders.

Yuriy Baglaenko, Catriona Wagner, Vijay G Bhoj, Petter Brodin, M Eric Gershwin, Daniel Graham, Pietro Invernizzi, Kenneth K Kidd, Ilya Korsunsky, Michael Levy and 9 more

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cambridge prisms. Precision medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 14 institutions in 3 countries.

Yuriy BaglaenkoBrigham and Women's Hospital, Boston, MA, USA.
Catriona WagnerAutoimmune Association, Clinton Township, MI, USA.
Vijay G BhojUniversity of Pennsylvania, Philadelphia, PA, USA.
Petter BrodinKarolinska Institute, Solna, Sweden.
M Eric GershwinUniversity of California, Davis, Davis, CA, USA.
Daniel GrahamThe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Pietro InvernizziDivision of Gastroenterology, Center for Autoimmune Liver Diseases, Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
Kenneth K KiddDepartment of Laboratory Medicine, Yale School of Medicine, New Haven, CT, USA.
Ilya KorsunskyBrigham and Women's Hospital, Boston, MA, USA.
Michael LevyMassachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Andrew L MammenNational Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, USA.
Victor NizetSchool of Medicine, University of California San Diego, San Diego, CA, USA.
Francisco Ramirez-ValleBristol Myers Squibb, New York, NY, USA.
Edward C StitesDepartment of Laboratory Medicine, Yale School of Medicine, New Haven, CT, USA.
Marc S WilliamsGeisinger, Danville, PA, USA.
Michael WilsonWeill Institute for Neurosciences, Department of Neurology, UCSF, San Francisco, CA, USA.
Noel R RoseAutoimmune Association, Clinton Township, MI, USA.
Virginia LaddAutoimmune Association, Clinton Township, MI, USA.
Marina SirotaBakar Computational Health Sciences Institute, UCSF, San Francisco, CA, USA.ORCID https://orcid.org/0000-0002-7246-6083
Autoimmune Technologies (United States) · USBrigham and Women's Hospital · USYale University · USAzienda Ospedaliera San Gerardo · ITBristol-Myers Squibb (United States) · USBroad Institute · USGeisinger Medical Center · USHarvard University · USKarolinska Institutet · SENational Institutes of Health · USNeurosciences Institute · USUniversity of California, Davis · USUniversity of California San Diego · USUniversity of Pennsylvania · US

Funding

RESOURCE-BASED CENTER FOR THE ADVANCEMENT OF PRECISION MEDICINE IN RHEUMATOLOGYP30AR070155 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Mary C Nakamura · 2016 to 2026
$8.2M
NIAMS NIH HHS P30 AR070155
6 · The paper itself

Abstract

Precision Medicine is an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle. Autoimmune diseases are those in which the body's natural defense system loses discriminating power between its own cells and foreign cells, causing the body to mistakenly attack healthy tissues. These conditions are very heterogeneous in their presentation and therefore difficult to diagnose and treat. Achieving precision medicine in autoimmune diseases has been challenging due to the complex etiologies of these conditions, involving an interplay between genetic, epigenetic, and environmental factors. However, recent technological and computational advances in molecular profiling have helped identify patient subtypes and molecular pathways which can be used to improve diagnostics and therapeutics. This review discusses the current understanding of the disease mechanisms, heterogeneity, and pathogenic autoantigens in autoimmune diseases gained from genomic and transcriptomic studies and highlights how these findings can be applied to better understand disease heterogeneity in the context of disease diagnostics and therapeutics.

Indexed as

Autoimmunitybioinformaticsdata integrationdiagnosisgenomics

Identifiers

PMID38550937
PMCPMC10953750
OpenAlexW4381276108

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.